Early trial backs use of artificial skin tissue
The UK's Intercytex has unveiled new early-stage data that supports its contention that an experimental artificial skin can reduce scarring. ICX-SKN is based on proteins found in wounds undergoing the healing process. Researchers have added fibroblasts to manufacture tissue that closely replicates the body's mechanism for developing new skin. The lab-made tissue was fully integrated in volunteers in 28 days. Squares of skin were cut from the bodies of six volunteers and replaced with the artificial tissue in the trial.
- read the Cosmetics Design report
Related Article:
Intercytex raises £12M in new venture round. Report
New type of cells developed for tissue repair. Report
Be the first to comment Rate it:
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets